Merck & Co., Inc.

MRK • Drug Manufacturers - General

$148.11

▼ -0.19 (-0.13%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$366.08B

Crecimiento

7.6%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 28.1%Crecimiento positivo de ingresos · 7.8%Flujo de caja libre positivo · 4.94Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 14.43

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 6 ago 2026, 1:22 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$148.11

Change-0.13%

Shares Out2.47B

Market Cap$366.08B

Enterprise Value$409.49B

52W Range77.58 - 135.05

Beta0.21

P/E40.97

P/S5.58

P/B7.98

P/FCF25.94

EV/Sales6.24

Price$148.11

Change-0.13%

Shares Out2.47B

Market Cap$366.08B

Enterprise Value$409.49B

52W Range77.58 - 135.05

Beta0.21

P/E40.97

P/S5.58

P/B7.98

P/FCF25.94

EV/Sales6.24

EV/EBITDA18.05

EV/FCF29.01

Earnings Yield2.44%

FCF Yield3.86%

Dividend Yield2.23%

Gross Margin71.98%

Oper. Margin36.17%

Profit Margin28.12%

Debt/Eq0.96

Current Ratio1.54

Quick Ratio1.30

Revenue 5Y7.61%

Target$158.22

Target Upside6.83%

Target Median$165.50

Target Range105.00 - 180.00

Volume7.60M

Avg Volume10.14M

EPS Surprise0.19

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

81/100

Potencial de crecimiento

Ingresos y expansión

80/100

Atractivo del precio

Barata o cara hoy

73/100

Por qué este puntaje▼

Márgenes estables o en mejora · 28.1%Crecimiento positivo de ingresos · 7.8%Flujo de caja libre positivo · 4.94Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 14.43Liquidez saludable · 1.54

Analyst view

Analyst sentiment and price target

MRK

Analyst sentiment

Based on 38 analyst votes · 2026-10-20

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-05

Bajo

$105.00

Promedio

$140.18

Mediana

$145.00

Alto

$155.00

Resumen de la compañía

IPO: 1/13/1978

Industria: Drug Manufacturers - General

P/B i: 7.98

Deuda / Patrimonio i: 0.96

Margen operativo: 36.17%

Margen neto: 28.12%

ROE i: -

ROIC: -

Salud financiera

Puntaje16 / 20

Deuda / Patrimonio: 0.96

Ratio corriente: 1.54

Ratio rápido: 1.30

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Coe Mary Ellen

Transacción: 06/30/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

07/01/2026

Tipo

COMPRA

Karsanbhai Surendralal Lanca

Transacción: 06/30/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

07/01/2026

Tipo

COMPRA

Seidman Christine E

Transacción: 06/30/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

07/01/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Coe Mary Ellen	COMPRA	—	Not reported	06/30/2026	07/01/2026
Karsanbhai Surendralal Lanca	COMPRA	—	Not reported	06/30/2026	07/01/2026
Seidman Christine E	COMPRA	—	Not reported	06/30/2026	07/01/2026
BAKER DOUGLAS M JR	COMPRA	—	Not reported	05/29/2026	06/02/2026
Craig Pamela J.	COMPRA	—	Not reported	05/29/2026	06/02/2026
GLOCER THOMAS H	COMPRA	—	Not reported	05/29/2026	06/02/2026
LAVIZZO-MOUREY RISA J	COMPRA	—	Not reported	05/29/2026	06/02/2026
Mayo Stephen	COMPRA	—	Not reported	05/29/2026	06/02/2026
Rothman Paul	COMPRA	—	Not reported	05/29/2026	06/02/2026
RUSSO PATRICIA F	COMPRA	—	Not reported	05/29/2026	06/02/2026
Seidman Christine E	COMPRA	—	Not reported	05/29/2026	06/02/2026
THULIN INGE G	COMPRA	—	Not reported	05/29/2026	06/02/2026
Coe Mary Ellen	COMPRA	—	Not reported	05/29/2026	06/02/2026
Karsanbhai Surendralal Lanca	COMPRA	—	Not reported	05/29/2026	06/02/2026
Warden Kathy J	COMPRA	—	Not reported	05/29/2026	06/02/2026
Guindo Chirfi	COMPRA	+6,628	Not reported	05/05/2026	05/07/2026
Guindo Chirfi	COMPRA	+19,402	$113.15	05/05/2026	05/07/2026
Smart Dalton E. III	COMPRA	+2,298	Not reported	05/05/2026	05/07/2026
Smart Dalton E. III	COMPRA	+5,045	$113.15	05/05/2026	05/07/2026
Oosthuizen Johannes Jacobus	COMPRA	+10,605	Not reported	05/05/2026	05/07/2026

Sobre la compañía

Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Fuente - Link

Competidores

ABT AMGN AZN GILD GSK NVO NVS PFE SNY TMO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now

Rose's Income Garden portfolio review highlights 15 most undervalued and 15 most overvalued dividend stocks using 52-week high/low analysis. Energy names like XOM, SHEL, and CVX have rotated into overvalued territory, while high-yield REITs such as VICI remain top undervalued picks. Dividend yield remains a key selection criterion, with several undervalued stocks offering yields above 5% and investment-grade credit ratings.

Seeking Alpha

Merck (MRK) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Merck (MRK) stood at $143.63, denoting a -1.59% move from the preceding trading day.

Zacks Investment Research

Silence Therapeutics jumps 59% on Merck takeover

Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 after agreeing to a $1.3 billion takeover by Merck KGaA, the German pharmaceutical and technology group. Merck will pay $20 in cash for each American depositary share (ADS), representing a 130% premium to Silence's closing price on October 16 and an 82% premium to its 30-day volume-weighted average price.

Proactive Investors

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

MarketBeat

Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings

Birch Hill Investment Advisors LLC lowered its holdings in Merck and Co., Inc. (NYSE: MRK) by 9.1% in the quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,932 shares of the company's stock after selling 8,040 shares during the period. Birch

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-30	-1.47	-1.28	0.19
2026-02-03	2.01	2.04	0.03
2025-10-30	2.36	2.58	0.22
2025-07-29	2.03	2.13	0.1
2025-04-24	2.13	2.22	0.09
2025-02-04	1.85	1.72	-0.13
2024-10-31	1.5	1.57	0.07
2024-07-30	2.15	2.28	0.13
2024-04-25	1.88	2.07	0.19
2024-02-01	-0.09	0.03	0.12
2023-10-26	1.95	2.13	0.18
2023-08-01	-2.17	-2.06	0.11